DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Transderm Nitro (Nitroglycerin Transdermal) - Summary



Transderm Nitro®

Nitroglycerin is 1,2,3-propanetriol, trinitrate, an organic nitrate.

Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack.

See all Transderm Nitro indications & dosage >>


Published Studies Related to Transderm Nitro (Nitroglycerin Transdermal)

Effect of the Addition of Vasopressin or Vasopressin Plus Nitroglycerin to Epinephrine on Arterial Blood Pressure during Cardiopulmonary Resuscitation in Humans. [2011.11]
Background: Infusion of a vasopressor during cardiopulmonary resuscitation (CPR) in humans increases end decompression (diastolic) arterial blood pressure, and consequently increases vital organ perfusion pressure and survival.

Nitroglycerin Ointment for the Prevention of Postmenopausal Osteoporosis (December). [2011.10.18]
OBJECTIVE:To determine whether clinical trial data support the use of nitroglycerin for prevention of postmenopausal osteoporosis.DATA SOURCES:A literature search using MEDLINE (1966-September 2011) and EMBASE (1973-September 2011) was conducted using the search terms nitroglycerin, bone mineral density, fracture, and osteoporosis...

The effect of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in acute/subacute stroke. [2011.08]
BACKGROUND: High blood pressure is a common complication in acute stroke and is associated with a poor outcome. Aims This study assesses the effects of transdermal glyceryl trinitrate on 24 h ambulatory blood pressure in patients with recent stroke... CONCLUSIONS: Transdermal glyceryl trinitrate (5 mg) significantly lowered 24 h blood pressure by 9/5 mmHg (equivalent to a 6% reduction) in both dipping and nondipping patients with acute/subacute stroke. This reduction in blood pressure is clinically relevant and is unlikely to be excessive. (c) 2011 The Authors. International Journal of Stroke (c) 2011 World Stroke Organization.

Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study. [2011.07]
CONCLUSIONS: The differential modulation effects of cystatin-C and interleukin-6 but not other inflammatory markers, in response to NES compared with NTG therapy, may provide important implications for vasodilator therapy. Further studies are warranted to confirm these findings. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00842023.

Short-term aerobic exercise reduces nitroglycerin-induced orthostatic intolerance in older adults with type 2 diabetes. [2011.06]
AIMS/HYPOTHESIS: Older adults are at a high risk for syncope due to orthostatic intolerance (OI), and this risk increases with comorbid type 2 diabetes and vasoactive medications. Despite many benefits, previous investigations have shown worsening OI with aerobic training. We examined whether aerobic exercise reduced OI in older adults with type 2 diabetes who were given a short-acting vasoactive agent (nitroglycerin)... CONCLUSIONS: Our findings indicate that a relatively short aerobic exercise intervention can improve postnitroglycerin orthostatic tolerance in older adults with type 2 diabetes.

more studies >>

Clinical Trials Related to Transderm Nitro (Nitroglycerin Transdermal)

Scopolamine to Treat Depression
This study will examine the antidepressant effects of scopolamine in patients with major depressive disorder or bipolar disorder. Scopolamine is commonly used to treat motion sickness and diarrhea, and is sometimes given before anesthesia or during eye examinations. In preliminary studies, scopolamine has shown strong antidepressant effects when given as an intravenous (through a vein) infusion. This study will examine its effectiveness when given through a skin patch and in pill form.

People between 18 and 50 years of age who have major depressive disorder or bipolar disorder may be eligible for this study. Candidates are screened with a physical exam, electrocardiogram (EKG), eye exam, blood and urine tests, psychiatric and clinical interviews and neuropsychological testing.

Participants wear skin patches behind the ear and take pills according to a prescribed regimen over an 8-week period. Half of the time the medications contain scopolamine and half of the time they contain an "active" placebo called glycopyrrolate, a drug that produces side effects similar to those that may be experienced with scopolamine, but that does not go into the brain.

Participants come to the NIH Clinical Center every 4 to 5 days while taking the medication and then for two follow-up visits over the next 2 weeks for a physical exam and evaluations with clinical rating scales. In addition, participants are asked to undergo two sessions of cognitive testing and to have two positron emission tomography (PET) studies. Those who have the PET scans also have a magnetic resonance imaging (MRI) scan. Participants can choose to participate in the rest of the study without doing the PET scan.

PET is a diagnostic imaging tool that uses a radioactive chemical "tracer" to show cellular activity in specific tissues of the body. For this procedure, a catheter (thin plastic tube) is placed into an arm vein for injecting the tracer, and a second catheter is inserted into an artery in the wrist to obtain arterial blood samples during the scan. The patient lies on the scanner bed, wearing a special mask that is placed over the head to limit movement during the scan. MRI uses a magnetic field and radio waves to produce pictures of the brain. For this test, the subject lies on a table that is moved into the scanner (a metal cylinder), wearing earplugs to muffle the noise of the machine during the scan.

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Recruiting]

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) [Recruiting]
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration.

Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) [Recruiting]
The primary objective of this study is to assess the safety of topical sirolimus (TD201) 1% for plantar keratoderma for the treatment of pachyonychia congenita. This study would also like to assess the potential of sirolimus (TD201) to improve the clinical severity of plantar keratoderma, including pain.

more trials >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015